TREA

97497978 - ETX

Follow

Information

  • Trademark
  • 97497978
  • Serial Number
    97497978
  • Registration Number
    7574266
  • Filing Date
    July 11, 2022
    2 years ago
  • Registration Date
    November 19, 2024
    3 months ago
  • Transaction Date
    November 19, 2024
    3 months ago
  • Status Date
    November 19, 2024
    3 months ago
  • Location Date
    November 18, 2024
    3 months ago
  • Status Code
    700
  • Current Location
    FILE REPOSITORY (FRANCONIA)
    Employee Name
    WOOD, CAROLINE
  • Attorney Docket Number
    210309.00021
    Attorney Name
    Anna King
  • Owners
Information
Mark Drawing Code
4
Mark Identification
ETX
Case File Statements
  • GS0401: Custom manufacture of pharmaceutical and medical preparations; custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; custom manufacture of RNAi-based pharmaceuticals and medicines; custom manufacture of short interfering RNA (siRNA) medicines; custom manufacture of nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid
  • GS0091: Downloadable and recorded computer software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the fields of pharmaceuticals, medicines and drug discovery; downloadable computer software using artificial intelligence for machine learning for use in the field of pharmaceuticals, medicines and drug discovery; recorded computer software using artificial intelligence for machine learning for use in the field of pharmaceuticals, medicines and drug discovery; downloadable databases in the field of pharmaceuticals, medicines and drug discovery; electronic databases recorded on computer media, for use in the field of pharmaceuticals, medicines and drug discovery; downloadable and recorded computer platform software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations; downloadable and recorded computer software platforms for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the fields of pharmaceuticals, medicines and drug discovery
  • GS0051: Pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; short interfering RNA (siRNA) medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation
  • GS0421: Scientific research and development; pharmaceutical research and development services; scientific research and development in the field of targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to RNAi-based pharmaceuticals and medicines; scientific, pharmaceutical and medical research and development services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking gene expression, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and, pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; drug discovery services; drug discovery services relating to RNAi-based pharmaceuticals and medicines; drug discovery services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; drug discovery services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; human genetic research; scientific and technical data analysis in the field of pharmaceuticals, medicines and drug discovery; scientific and technical data analysis in relation to pharmaceuticals and medicines; scientific and technical data analysis in relation to RNAi-based medicines; scientific and technical data analysis in relation to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific and technical data analysis in relation to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design, development, creation and maintenance of computer platforms and computer software; design, development, creation and maintenance of computational computer software platforms; design, development, creation and maintenance of computer software platforms and computer software for use in the field of pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) featuring computer software platforms for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the field of pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines and drug discovery, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines, and drug discovery, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating RNAi-based medicines and pharmaceuticals, short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design and development of computer-simulated models; design of computer-simulated models for use in the field of pharmaceuticals, medicines and drug discovery; providing temporary use of online non-downloadable computer software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the field of pharmaceuticals, medicines and drug discovery; providing temporary use of online non-downloadable computer software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the field of pharmaceuticals, medicines and drug discovery; Software as a Service (SaaS); Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines and drug discovery, namely, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and generating pharmaceutical and medical preparations; Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning for use in the field of pharmaceuticals, medicines and drug discovery, namely, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating RNAi-based medicines and pharmaceuticals, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid
Case File Event Statements
  • 7/14/2022 - 2 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 7/29/2022 - 2 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 4/19/2023 - a year ago
    3 - TEAS VOLUNTARY AMENDMENT RECEIVED Type: PARI
  • 4/25/2023 - a year ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 4/27/2023 - a year ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 4/27/2023 - a year ago
    6 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 4/27/2023 - a year ago
    7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 6/26/2023 - a year ago
    8 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 11/30/2023 - a year ago
    9 - ASSIGNED TO LIE Type: ALIE
  • 11/30/2023 - a year ago
    10 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 11/30/2023 - a year ago
    11 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 1/5/2024 - a year ago
    12 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 1/5/2024 - a year ago
    13 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 1/5/2024 - a year ago
    14 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 1/5/2024 - a year ago
    15 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 2/7/2024 - a year ago
    16 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 2/7/2024 - a year ago
    17 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 2/7/2024 - a year ago
    18 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 4/30/2024 - 10 months ago
    21 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 4/30/2024 - 10 months ago
    20 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 4/30/2024 - 10 months ago
    19 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 6/5/2024 - 9 months ago
    22 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 6/5/2024 - 9 months ago
    23 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 6/5/2024 - 9 months ago
    24 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 8/27/2024 - 6 months ago
    25 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 8/28/2024 - 6 months ago
    26 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 8/28/2024 - 6 months ago
    27 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 10/7/2024 - 5 months ago
    28 - APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER Type: CNTA
  • 11/19/2024 - 3 months ago
    29 - REGISTERED-SUPPLEMENTAL REGISTER Type: R.SR